Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

PURPOSE: In the treatment of patients with high-risk neuroblastoma, different doses of (131)I-metaiodobenzylguanidine ((131)I-MIBG) are administered at different time points during treatment. Toxicity, mainly haematological (thrombocytopenia), from (131)I-MIBG therapy is known to occur in extensivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Bleeker, Gitta, Schoot, Reineke A., Caron, Huib N., de Kraker, Jan, Hoefnagel, Cees A., van Eck, Berthe L., Tytgat, Godelieve A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788185/
https://www.ncbi.nlm.nih.gov/pubmed/23921531
http://dx.doi.org/10.1007/s00259-013-2510-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788185/
https://www.ncbi.nlm.nih.gov/pubmed/23921531
http://dx.doi.org/10.1007/s00259-013-2510-z

Ejemplares similares